A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Open Access
- 14 March 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 133 (11) , 1201-1204
Abstract
Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibitor palbociclib can overcome ibrutinib resistance in primary human MCL cells and MCL cell lines expressing wild-type Bruton’s tyrosine kinase (BTK). Therefore, we conducted a phase 1 trial to evaluate the dosing, safety, and preliminary activity of palbociclib plus ibrutinib in patients with previously treated mantle cell lymphoma. From August 2014 to June 2016, a total of 27 patients (21 men, 6 women) were enrolled. The maximum tolerated doses were ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle. The dose-limiting toxicity was grade 3 rash. The most common grade 3 to 4 toxicities included neutropenia (41%), thrombocytopenia (30%), hypertension (15%), febrile neutropenia (15%), and lung infection (11%). The overall and complete response rates were 67% and 37%, and with a median follow-up of 25.6 months, the 2-year progression-free survival was 59.4% and the 2-year response duration was 69.8%. A phase 2 multicenter clinical trial to further characterize efficacy is now ongoing. The current trial was registered at www.clinicaltrials.gov as #NCT02159755.Keywords
This publication has 11 references indexed in Scilit:
- Faculty Opinions recommendation of Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.2018
- Faculty Opinions recommendation of Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.2018
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaNew England Journal of Medicine, 2018
- Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trialThe Lancet Haematology, 2018
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialThe Lancet, 2018
- Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutationsOncotarget, 2016
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481SBTKMutation Revealed by Longitudinal Functional Genomics in Mantle Cell LymphomaCancer Discovery, 2014
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaBlood, 2012
- Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMolecular Cancer Therapeutics, 2004